



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

Mail Stop 4720

December 17, 2015

Via E-mail

Laurie D. Stezer  
Senior Vice President and Chief Financial Officer  
Halozyme Therapeutics, Inc.  
11388 Sorrento Valley Road  
San Diego, CA 92121

**Re: Halozyme Therapeutics, Inc.  
Form 10-K for the Fiscal Year Ended December 31, 2014  
Filed March 2, 2015  
Form 10-Q for the Fiscal Quarterly Period Ended June 30, 2015  
Filed August 10, 2015  
File No. 001-32335**

Dear Ms. Stezer:

We have reviewed your November 20, 2015 response to our comment letter and have the following comment.

Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to the comment, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our October 26, 2015 letter.

Form 10-Q for the Quarterly Period Ended June 30, 2015  
Notes to Condensed Consolidated Financial Statements  
4.Collaborative Agreements  
Other Collaborations, page 19

1. Refer to your response to our prior comment one. Please provide us proposed disclosure to be included in future periodic filings addressing:
  - In your summary of significant accounting policies' note the accounting policy you follow for the right of your collaborators to elect additional targets in the future; and

Laurie D. Stezer  
Halozyme Therapeutics, Inc.  
December 17, 2015  
Page 2

- For each applicable agreement discussed in this note, the dollar amount to elect the additional target and your conclusion as to whether the right is substantive and not priced at a more than insignificant discount.

You may contact Ibolya Ignat, Staff Accountant, at (202) 551-3636 if you have any questions regarding the comment. In this regard, do not hesitate to contact me at (202) 551-3679.

Sincerely,

/s/ Jim B. Rosenberg

Jim B. Rosenberg  
Senior Assistant Chief Accountant  
Office of Healthcare and Insurance